Lantern Pharma and Hoth Therapeutics Partner to Use AI Platform for Neurological Drug Development
TL;DR
Lantern Pharma's AI platform gives Hoth Therapeutics a competitive edge by reducing drug development risk and accelerating neurological treatment timelines with 94% accuracy.
Lantern Pharma's PredictBBB.ai platform uses AI algorithms to systematically predict blood-brain barrier penetration, streamlining candidate selection and development processes.
This AI-driven collaboration accelerates life-changing neurological therapies to patients, improving treatment outcomes and quality of life for those with brain disorders.
Lantern Pharma's AI platform can predict blood-brain barrier penetration with 94% accuracy, revolutionizing how neurological drugs are developed and tested.
Found this article helpful?
Share it with your network and spread the knowledge!
Lantern Pharma Inc. has entered into a strategic partnership with Hoth Therapeutics to deploy its artificial intelligence platform PredictBBB.ai for streamlining drug development processes. The collaboration focuses on utilizing AI technology to predict whether drug candidates can effectively cross the blood-brain barrier, a significant challenge in developing treatments for neurological conditions. The PredictBBB.ai platform demonstrates 94% accuracy in predicting blood-brain barrier penetration capabilities, representing a substantial advancement in drug development methodology.
This technology integration aims to reduce development risks, improve candidate selection processes, and accelerate overall drug development timelines for neurological treatments. The platform forms part of Lantern Pharma's broader RADR platform, which applies artificial intelligence and machine learning to optimize oncology drug discovery and development. Company leaders from both organizations have characterized the collaboration as a pivotal step toward accelerating the development pathway for bringing life-changing therapies to patients suffering from neurological conditions.
The partnership leverages Lantern Pharma's expertise in AI-driven drug development alongside Hoth Therapeutics' focus on innovative therapeutic approaches. Additional information about Lantern Pharma's developments can be found at https://ibn.fm/LTRN, while the full announcement details are available at https://ibn.fm/NZoZD. The deployment of PredictBBB.ai through this partnership represents a significant advancement in applying artificial intelligence to overcome one of the most challenging barriers in neurological drug development.
The blood-brain barrier has historically presented substantial obstacles for drug developers, often preventing potentially effective treatments from reaching their intended targets in the brain. This collaboration marks an important step in addressing this long-standing challenge through technological innovation. The 94% accuracy rate of the PredictBBB.ai platform offers a promising solution to a problem that has hindered neurological drug development for decades, potentially opening new pathways for treating conditions that have remained difficult to address with conventional pharmaceutical approaches.
Curated from InvestorBrandNetwork (IBN)
